How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tebentafusp for treating advanced uveal melanoma

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Tebentafusp is not recommended, within its marketing authorisation, for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.

1.2 This recommendation is not intended to affect treatment with tebentafusp that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

There is no standard treatment for HLA-A*02:01-positive advanced uveal melanoma. Usually people are offered immunotherapies licensed for treating cutaneous melanoma, such as pembrolizumab, or chemotherapy. Tebentafusp aims to treat the specific features of HLA-A*02:01-positive uveal melanoma.

Clinical trial evidence suggests that tebentafusp could increase how long people live and the length of time before their cancer gets worse compared with the usual treatments offered, but this is uncertain.

Tebentafusp meets the criteria for a life-extending treatment at the end of life. Because of the clinical uncertainty, the cost-effectiveness estimates are uncertain. They are also all higher than what NICE considers an acceptable use of NHS resources for end of life treatments. So, tebentafusp is not recommended.